SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,769,530 | +3815.0% | 603,962 | +5090.0% | 0.02% | – |
| Q2 2022 | $224,000 | -88.2% | 11,637 | -89.4% | 0.00% | -100.0% |
| Q1 2022 | $1,906,000 | +650.4% | 109,618 | +842.0% | 0.00% | – |
| Q4 2021 | $254,000 | +14.4% | 11,637 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $222,000 | -94.8% | 11,637 | -93.9% | 0.00% | -95.7% |
| Q4 2020 | $4,265,000 | +630.3% | 191,788 | +260.1% | 0.02% | +283.3% |
| Q1 2020 | $584,000 | – | 53,265 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |